HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Take the CME quiz: Vol. 10 No. 7, July 2009 E-Letters: Submit a response Alert me when this article is cited Alert me when E-Letters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Warren, J. B. Articles by Anderson, J. M. PubMed Articles by Warren, J. B. Articles by Anderson, J. M. Social Bookmarking                         What's this?

NeoReviews Vol.10 No.7 2009 e351
© 2009 American Academy of Pediatrics

Core Concepts

Respiratory Distress Syndrome

^* Oregon Health and Science University, Portland, Ore

Respiratory distress syndrome (RDS) is seen primarily in the preterm neonate and is due mostly to pulmonary surfactant deficiency. Lung atelectasis leads to ventilation-perfusion mismatching, hypoxia, and eventual respiratory failure in the untreated infant who has RDS. RDS is diagnosed by physical findings consistent with respiratory distress and characteristic radiographic findings. Treatment of RDS begins antenatally with the administration of maternal steroids to women at risk of preterm delivery between 24 and 34 weeks’ gestation. The use of repeat doses of antenatal steroids is under investigation but is currently not recommended outside of randomized, controlled trials. SRT has been approved for use since 1990 and has been successful in decreasing rates of RDS. Natural surfactant is currently recommended for use, but synthetic surfactant that contains proteins to mimic surfactant proteins is being investigated. In general, prophylactic use of surfactant is recommended over rescue treatment in infants at high risk for developing RDS, but the determination of which infants are at high risk for developing RDS remains a clinical one. The push toward use of less invasive ventilation strategies in the treatment of RDS has led to several trials of nasal continuous positive airway pressure (nCPAP). Results of the SUPPORT trial are pending, but the COIN trial has concluded that nCPAP use in infants who have RDS is not detrimental. Inhaled nitric oxide for RDS still requires investigation on safety and efficacy. Several other treatments have been studied, but as of yet, only inositol administration shows promise in the treatment of RDS. Several complications of the recommended treatments for RDS have been identified, but the benefits far outweigh the risks. Finally, there remains a need for long-term follow-up studies on preterm infants treated for RDS to assess neurodevelopmental outcomes.

Abbreviations: AT: antithrombin • BPD: bronchopulmonary dysplasia • CLD: chronic lung disease • FRC: functional residual capacity • GBS: group B Streptococcus • iNO: inhaled nitric oxide • IVH: intraventricular hemorrhage • nCPAP: nasal continuous positive airway pressure • NIH: National Institutes of Health • NIMV: nasal intermittent mandatory ventilation • PIE: pulmonary interstitial emphysema • PVL: periventricular leukomalacia • RDS: respiratory distress syndrome • SP: surfactant protein • SRT: surfactant replacement therapy

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?